Toll Free: 1-888-928-9744

Regulus Therapeutics Inc. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Regulus Therapeutics Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Regulus Therapeutics Inc. - Product Pipeline Review - 2014', provides an overview of the Regulus Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Regulus Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Regulus Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Regulus Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Regulus Therapeutics Inc.'s pipeline products

Reasons to buy

- Evaluate Regulus Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Regulus Therapeutics Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Regulus Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Regulus Therapeutics Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regulus Therapeutics Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Regulus Therapeutics Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Regulus Therapeutics Inc. Snapshot 5
Regulus Therapeutics Inc. Overview 5
Key Information 5
Key Facts 5
Regulus Therapeutics Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Regulus Therapeutics Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Regulus Therapeutics Inc. - Pipeline Products Glance 10
Regulus Therapeutics Inc. - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Regulus Therapeutics Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Regulus Therapeutics Inc. - Drug Profiles 13
RG-101 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Anti microRNA-103/107 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Anti microRNA-10b 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Anti microRNA-122 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Anti microRNA-21 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
miR-221 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RG-012 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
miR-19 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Oligonucleotide to Inhibit Micro-RNA for Metabolic Disease 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Regulus Therapeutics Inc. - Pipeline Analysis 26
Regulus Therapeutics Inc. - Pipeline Products by Target 26
Regulus Therapeutics Inc. - Pipeline Products by Route of Administration 27
Regulus Therapeutics Inc. - Pipeline Products by Molecule Type 28
Regulus Therapeutics Inc. - Pipeline Products by Mechanism of Action 29
Regulus Therapeutics Inc. - Recent Pipeline Updates 30
Regulus Therapeutics Inc. - Dormant Projects 33
Regulus Therapeutics Inc. - Discontinued Pipeline Products 34
Discontinued Pipeline Product Profiles 34
Anti microRNA-33a/b 34
Regulus Therapeutics Inc. - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37
List of Tables
Regulus Therapeutics Inc., Key Information 5
Regulus Therapeutics Inc., Key Facts 5
Regulus Therapeutics Inc. - Pipeline by Indication, 2014 7
Regulus Therapeutics Inc. - Pipeline by Stage of Development, 2014 8
Regulus Therapeutics Inc. - Monotherapy Products in Pipeline, 2014 9
Regulus Therapeutics Inc. - Phase I, 2014 10
Regulus Therapeutics Inc. - Preclinical, 2014 11
Regulus Therapeutics Inc. - Discovery, 2014 12
Regulus Therapeutics Inc. - Pipeline by Target, 2014 26
Regulus Therapeutics Inc. - Pipeline by Route of Administration, 2014 27
Regulus Therapeutics Inc. - Pipeline by Molecule Type, 2014 28
Regulus Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2014 29
Regulus Therapeutics Inc. - Recent Pipeline Updates, 2013 30
Regulus Therapeutics Inc. - Dormant Developmental Projects, 2014 33
Regulus Therapeutics Inc. - Discontinued Pipeline Products, 2014 34 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify